Dr. Kenneth Bloom, from Chief Medical Officer at Clarient, Explains Situations Requiring HER2 Retesting
Kenneth J. Bloom, MD
Advertisement
Articles by Kenneth J. Bloom, MD
Dr. Kenneth Bloom, the Chief Medical Officer at Clarient, Compares HER2 Screening Assays
Advertisement
Latest Updated Articles
Dr. Bloom Compares HER2 Screening AssaysJanuary 30th 2012
Dr. Bloom Explains Situations Requiring HER2 RetestingFebruary 16th 2012
Advertisement
Advertisement
Trending on OncLive
1
ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC
2
From Toilet Cleaner to Thoracic Oncologist and Patient: How Ross Camidge Built a Life Worth Loving
3
Breast Cancer Experts Spotlight Practice-Informing and Thought-Provoking Data From ASCO 2026
4
FDA Grants Priority Review to Giredestrant for ER-Positive Early Breast Cancer
5